Opinion|Videos|June 19, 2024
Triaging and Prioritizing Patients with Multiple Myeloma
Experts on multiple myeloma provide clinical insights on how they triage and prioritize patients to best utilize available resources.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for CAR T-cell therapy from community practices?
Advertisement
Related to this article
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma
5